Misonidazole neuropathy. A prospective study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • B Melgaard, Denmark
  • O Køhler
  • ,
  • H Sand Hansen
  • ,
  • Jens Overgaard
  • J Munck-Hansen
  • ,
  • Olaf B. Paulson, Denmark
The frequency with which polyneuropathy developed was investigated in patients with cancer of the larynx and pharynx who participated in a double-blind trial of the radiosensitizing drug misonidazole. Fourteen of 36 patients receiving misonidazole (total dose of about 11 g/m2) developed neuropathy, while this occurred in only 2 of 34 patients in the placebo group. Vibration perception threshold increased in all patients who developed neuropathy, but also in 12 (5 misonidazole and 7 placebo treated) without other symptoms or signs of neuropathy. Pharmacokinetic studies of misonidazole revealed a correlation between development of neuropathy and a high 'peak plasma concentration/g misonidazole in each fraction' and especially a high 'area under plasma concentration curve/g misonidazole in each fraction'.
Original languageEnglish
JournalJournal of Neurooncology
Pages (from-to)227-230
Number of pages4
Publication statusPublished - Nov 1988

    Research areas

  • Adult, Aged, Aged, 80 and over, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Laryngeal Neoplasms, Male, Middle Aged, Misonidazole, Nervous System Diseases, Pharyngeal Neoplasms

See relations at Aarhus University Citationformats

ID: 63359105